Table 1.
Patient and tumor characteristics.
| Total (N=501) | |
|---|---|
| Age (N=499) | 57.7(21.7,83.9) |
| Previous Other Cancer (N=478) | |
| No | 466(97.5) |
| Yes | 12(2.5) |
| Family Other Cancer (N=463) | |
| No | 300(64.8) |
| Yes | 163(35.2) |
| Initial stage (N=496) | |
| I | 58(11.7) |
| II | 33(6.7) |
| III | 350(70.6) |
| IV | 55(11.1) |
| PS (N=478) | |
| 0 | 357(74.7) |
| 1 | 92(19.2) |
| 2 | 26(5.4) |
| 3 | 3(0.63) |
| Histology (N=501) | |
| HGSOC | 377(75.2) |
| LGSOC | 11(2.2) |
| Clear cell | 30(6.0) |
| Endometrioid | 58(11.6) |
| Mucinous | 25(5.0) |
| Surgery (N=488) | |
| No | 3(0.6) |
| Yes | 485(99.4) |
| Type of surgery (N=478)* | |
| BSO | 18(3.8) |
| TAH & BSO | 392(82.0) |
| TAH & USO | 35(7.3) |
| USO | 5(1.0) |
| Other | 28(5.9) |
| Residual disease (N=307)* | |
| 0 cm | 143(46.6) |
| <2 cm | 75(24.4) |
| 2-5 cm | 48(15.6) |
| >5 cm | 41(13.4) |
| Chemotherapy (N=488) | |
| No | 2(0.41) |
| Yes | 486(99.6) |
| Type of treatment (N=486) | |
| Adjuvant | 13(2.7) |
| Front-line | 473(97.3) |
Values presented as Median (min, max) or N (column %).
*Percentages for the type of surgery and residual disease were calculated out of the total number of patients with available data that had undergone surgery.
BSO, bilateral salpingo-oophorectomy; HGSOC, high-grade serous ovarian cancer; LGSOC, low-grade serous ovarian cancer; N, number; TAH, total abdominal hysterectomy; USO, unilateral salpingo-oophorectomy.